Much ink has been spilled on the increasing number of private equity sponsors
and cash-rich strategics chasing after the same limited pool of quality targets.
Much less attention has been paid to what we see as a growing and important
trend: transactions involving private equity sponsors “teaming up” with strategics
in innovative ways that unlock value for both sides. Recent transactions illustrate
the various forms these partnerships can take:
- The sponsor and the strategic team up to acquire a business, as when
OptumHealth and Summit Partners joined forces to acquire Sound Physicians
or when KKR teamed with HCA Healthcare to acquire Envision Healthcare.
- A strategic sells a stake in an existing business to a sponsor, such as Thomson
Reuters’ sale of its majority stake in its Financial & Risk unit to Blackstone.
- A strategic buys a stake in a sponsor-owned portfolio company, such as
Tenet Healthcare’s acquisition of United Surgical Partners, a portfolio company
of Welsh, Carson, Anderson & Stowe (WCAS).
Data from Capital IQ indicates that there were 13 transactions involving some form
of sponsor-strategic partnership out of 43 private equity buyouts with deal values in
excess of $500 million that were announced between January 2017 and September
2019. According to PitchBook, over 10% of private equity buyouts in 2018 with
deal values in excess of $1 billion involved sponsor-strategic partnerships (in 2019
(through the beginning of October), that figure is closer to 15%).
A number of sponsor-strategic
partnership transactions have been
concentrated in the healthcare sector,
where we have seen sponsors leverage
partnerships with corporate buyers
to navigate regulatory requirements
and exploit commercial opportunities.
Indeed, according to the 2019
Bain Global Healthcare Private
Equity Report, in 2018, there were
18 sponsor-strategic partnership
deals in the healthcare sector that
accounted for $7.9 billion, or 12.5% of
disclosed value. Further, KKR/HCA’s
acquisition of Envision Healthcare and
OptumHealth/Summit’s acquisition
of Sound Physicians mentioned above
were among the 10 largest healthcare
deals of 2018.
Advantages of Sponsor-
Strategic Partnerships
From the sponsor’s perspective, partnering
with a strategic to acquire a business offers
a number of important advantages:
The partnership may distinguish
the sponsor in a competitive process
and allow it to tap into synergies
and additional sources of capital to
afford higher valuation multiples and
participate in larger deals
The strategic partner may give the
acquired business access to more
markets, distribution networks,
commercial opportunities and
economies of scale than a sponsor
alone could offer
A strategic partner can help mitigate
concerns that shareholders and
regulators may have regarding a
private equity buyer, particularly in
regulated sectors such as healthcare
and insurance
Alternatively, if a stand-alone
acquisition by a strategic presents
antitrust or other regulatory issues, a
sponsor-strategic partnership might
allow the partners to “split” the business
to avoid such hurdles and create a
transaction that could not be completed
by either partner acting alone
A strategic partner may provide an
opportunity for a sponsor to buy
a target company and “split” the
business based on the assets that are
more attractive to each of the sponsor
or the strategic partner in order to
maximize overall value
If the strategic partner has a strong
credit rating, a sponsor can often
access cheaper debt financing
A strategic partner may provide a builtin
exit opportunity for the sponsor
Recent sponsor-strategic partnership
transactions illustrate some of these
points. Take, for example, the ability
to have a clear exit for the sponsor. In
2017, TPG and WCAS teamed with
Humana to acquire the hospice business
of Kindred. The following year, the
consortium acquired Curo Health
Services for $1.4 billion, which it then
combined with Kindred to create the
largest hospice provider in the United
States. The parties hardwired a path
to exit by agreeing to a series of put/
call mechanics that enable TPG and
WCAS to put their shares in Kindred
(after reflecting the addition of Curo)
to Humana after a period of three
years, with an exercise price multiple
determined by certain agreed-upon
valuation metrics. Similarly, in 2015,
Tenet Healthcare paid $425 million
to buy a controlling stake in United
Surgical Partners, a portfolio company
of WCAS, and negotiated a put/call
structure that gave Tenet a path to full
ownership over five years. In 2018,
Tenet announced it had completed the
purchase of WCAS’s remaining stake.
The OptumHealth/Summit
acquisition of a controlling interest
in Sound Physicians, a physician
staffing company, showcased both
the commercial advantages of a
strategic partner and the effect on the
target’s credit ratings. According to
a ratings report by Moody’s, the B1
Corporate Family rating they gave
Sound Physicians is supported by
its “leading position” as a hospitalist
provider and Moody’s opinion that
the company is “better aligned with
hospitals and payers than many other
physician staffing companies” in light
of OptumHealth’s ownership stake in
the company.
Benefits of sponsor-strategic
partnerships accrue to the strategic as
well. These include deal sourcing for
potential add-on acquisitions, better
management rollover packages to
help retain and motivate management
and key employees, and expertise in
rationalizing the target’s business
and improving its efficiency. More
importantly, a partnership with a private
equity firm provides the strategic with
the opportunity to learn a new business
over an extended period of time with less
economic exposure.
In deals where a strategic sells a piece
of an existing business to a sponsor but
continues to maintain a sizable position
in the investment, the strategic may
partner with the sponsor to avoid a
lengthy auction process, deconsolidate
a (typically underperforming) business,
refocus its resources and management
attention to its core business and record
a gain on sale, while continuing to
participate in the upside of the business
under the stewardship of the sponsor
until an ultimate exit. Examples of such
transactions include the 2018 sale
by AmTrust of 51% of its U.S.-based
fee business to Madison Dearborn
and the 2017 sale by FIS of 60% of its
management consulting business to
Clayton, Dubilier & Rice.
Challenges of Structuring
Sponsor-Strategic Partnerships
Although sponsor-strategic partnerships
can offer clear advantages, realizing
these benefits requires time, effort and
commitment. For one thing, incentives
may not always be aligned: a sponsor
may have a three-to-five-year horizon,
whereas a strategic may have a longerterm
focus. A sponsor and a strategic
may also have differing views about
the optimal exit scenario. For example,
a strategic may want restrictions on
the ability of the sponsor to sell to the
strategic’s competitors. A strategic buyer
may be sensitive to certain issues that
are of less concern to sponsors, such as
regulatory matters and other aspects of
the target that may affect the strategic
buyer’s ongoing business.
These partnerships may provide sponsors with a leg up in
competitive bidding, a clear exit plan and access to more markets,
while strategics may get access to increased deal flow, better
packages to retain and motivate management and expertise in
improving the efficiency of the new business.
Moreover, the key terms of these
partnerships – which are often complex
and critical to a successful outcome –
may have to be negotiated in the midst
of a fast-moving auction process, and
sponsors are often better positioned to
make decisions and act quickly than a
large strategic buyer. It may be difficult
to agree on the terms of a partnership
in time to win a bid, or alternatively,
parties may decide to work out specifics
after a deal has signed, only to find
that they lack a clear understanding
of each other’s interests and goals. In
deals where the sponsor-strategic value
proposition includes entry into longterm
commercial relationships between
the acquired business and the strategic,
these issues can be particularly acute, as
negotiating those arrangements often
requires the input of target management,
access to whom can be difficult outside
of a proprietary process.
Overall, it is critical for the partners to
develop a good working relationship, if
one doesn't already exist, and establish
trust early on in the transaction in order
to set themselves up to be successful.
Best Practices for Sponsor-
Strategic Partnerships
While every sponsor-strategic
partnership is different, there are a
number of best practices that sponsors
should keep in mind when considering
these combinations:
- Define the partnership at the
outset. Discuss the goals of each
party up front. Agree to the greatest
extent possible on key issues with
respect to partnership governance
and go-forward arrangements,
including post-acquisition board
composition and veto rights.
- Have the exit in sight. Formulate a
common understanding of when and
how the sponsor will exit the deal and
discuss potential exit mechanisms,
including a right of offer/first refusal,
put/call rights (including pricing
mechanism for a put/call, although it
may be difficult to agree on a put or call
price in advance) and drag-along rights.
It can take work to align the interests of sponsors and strategics,
with possible sticking points, including different investment
horizons, sensitivity to potential regulatory issues and restrictions
on selling the new company to competitors.
- Consider the implications.
Anticipate the projected impact
the partnership will have on the
contemplated transaction, including
the partnership’s effect on substantive
antitrust analysis and possible
additional regulatory requirements.
In the case of a publicly traded target,
consider whether the combined
holdings of a sponsor and a strategic
partner make them subject to earlywarning
disclosures and, in some
jurisdictions, formal tender offer
and bid requirements.
- Focus on the presentation to the
seller. Consider how best to present
an attractive and unified message
regarding the partnership to a
seller throughout the bid process.
Predict seller concerns with the
sponsor-strategic partnership bid and
proactively offer solutions to avoid a
seller discounting the partnership
bid as too complicated or conditional
to get done.
- Be flexible and creative. These
transactions generally require
solution-oriented and creative
dealmakers to work through issues
efficiently and commercially to
keep the deal on track. Consider
establishing “rules of the road” up
front to be able to move quickly
to respond to changing auction
dynamics and other deal issues that
will inevitably arise throughout
the bidding, negotiation and even
implementation phases.
Armed with an understanding of
what issues have the greatest potential
to create problems down the line, deal
teams can prioritize resolving those
issues earlier in the process, enabling
the parties to focus on working
together to bring a transaction over the
finish line, and ultimately maximize the
value of their partnership to achieve
a successful investment outcome for
both the sponsor and strategic partner.
The Private Equity Report Fall, 2019, Vol 19, No 2